Clinical Trial Update: Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating pyrotinib in combination with docetaxel as first-line treatment for HER2-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN